This paper is in the following e-collection/theme issue:

Surveillance Reports (139) Cancer Survivorship (262) Cancer Epidemiology, Cancer Surveillance and Infodemiology (78) Obstetrics, Gynecology, and Reproductive Medicine (235) Surveillance Systems (466) Innovative Methods in Public Health and Surveillance (336) Clinical Cancer Research (88) Health Care Quality and Health Services Research (275) Longitudinal and Cohort Studies in Public Health (316) Statistical Methods for Surveillance and Population Health (158)

Published on in Vol 7, No 11 (2021): November

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/25976, first published .
Long-Term Survival Among Histological Subtypes in Advanced Epithelial Ovarian Cancer: Population-Based Study Using the Surveillance, Epidemiology, and End Results Database

Long-Term Survival Among Histological Subtypes in Advanced Epithelial Ovarian Cancer: Population-Based Study Using the Surveillance, Epidemiology, and End Results Database

Long-Term Survival Among Histological Subtypes in Advanced Epithelial Ovarian Cancer: Population-Based Study Using the Surveillance, Epidemiology, and End Results Database

Authors of this article:

Shi-Ping Yang1 Author Orcid Image ;   Hui-Luan Su2 Author Orcid Image ;   Xiu-Bei Chen3 Author Orcid Image ;   Li Hua4 Author Orcid Image ;   Jian-Xian Chen5 Author Orcid Image ;   Min Hu4 Author Orcid Image ;   Jian Lei4 Author Orcid Image ;   San-Gang Wu3 Author Orcid Image ;   Juan Zhou4 Author Orcid Image
Article Authors Cited by (12) Tweetations (6) Metrics

Journals

  1. Pitiyarachchi O, Friedlander M, Java J, Chan J, Armstrong D, Markman M, Herzog T, Monk B, Backes F, Secord A, Bonebrake A, Rose P, Tewari K, Lentz S, Geller M, Copeland L, Mannel R. What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer. Gynecologic Oncology 2022;166(3):410 View
  2. Hua T, Zhao B, Fan S, Zhao C, Kong Y, Tian R, Zhang B. Prognostic implications of PPL expression in ovarian cancer. Discover Oncology 2022;13(1) View
  3. Cao H, Yang Y, Huang B, Zhang Y, Wu Y, Wan Z, Ma L. A cross-sectional study of the association between heavy metals and pan-cancers associated with sex hormones in NHANES 1999–2018. Environmental Science and Pollution Research 2023;30(21):61005 View
  4. Wang T, Fu X, Zhang L, Liu S, Tao Z, Wang F, Cui D. Prognostic Factors and a Predictive Nomogram of Cancer-Specific Survival of Epithelial Ovarian Cancer Patients with Pelvic Exenteration Treatment. International Journal of Clinical Practice 2023;2023:1 View
  5. Liu X, Jin S, Zi D. Overall survival prediction models for gynecological endometrioid adenocarcinoma with squamous differentiation (GE-ASqD) using machine-learning algorithms. Scientific Reports 2023;13(1) View
  6. Hosseini M, Bejnordi B, Trinh V, Chan L, Hasan D, Li X, Yang S, Kim T, Zhang H, Wu T, Chinniah K, Maghsoudlou S, Zhang R, Zhu J, Khaki S, Buin A, Chaji F, Salehi A, Nguyen B, Samaras D, Plataniotis K. Computational pathology: A survey review and the way forward. Journal of Pathology Informatics 2024;15:100357 View
  7. Wang M, Bi Y, Jin Y, Zheng Z. Global Incidence of Ovarian Cancer According to Histologic Subtype: A Population-Based Cancer Registry Study. JCO Global Oncology 2024;(10) View
  8. Standing D, Dandawate P, Gunewardena S, Covarrubias-Zambrano O, Roby K, Khabele D, Jewell A, Tawfik O, Bossmann S, Godwin A, Weir S, Jensen R, Anant S. Selective targeting of IRAK1 attenuates low molecular weight hyaluronic acid-induced stemness and non-canonical STAT3 activation in epithelial ovarian cancer. Cell Death & Disease 2024;15(5) View
  9. Olaoye T, ‐ A, Boyle W, Williams A, Ganesan R, Subba K, Goyal A, Leung E, Chowdhary R, Pascoe J, Williams S, Yap J, Balega J, Kumar S, Singh K, Sundar S. Investigating age and ethnicity as novel high-risk phenotypes in mucinous ovarian cancer: retrospective study in a multi-ethnic population. International Journal of Gynecologic Cancer 2024;34(9):1399 View
  10. Steventon L, Man K, Nicum S, Miller R, Peleg Hasson S, Shah S, Baser M, Kipps E, Forster M, Almossawi O, Chambers P. The impact of inter-cycle treatment delays on overall survival in patients with advanced-stage ovarian cancer. The Oncologist 2024;29(11):e1532 View
  11. Madariaga A, Sánchez-Bayona R, Kasherman L, Estrada-Lorenzo J, Manso L, Tolosa P, Alva M, Lema L, González-Deza C, Ciruelos E, Valcarcel D, Lheureux S, Oza A. Proactive assessment of patient reported outcomes in ovarian cancer studies: a systematic review and call for action in future studies. International Journal of Gynecologic Cancer 2024:ijgc-2024-005883 View
  12. Waddell S, Zhao G, Liu Z, Chen H, Zhang W, Wang Y, Miller D, Yue J, Li W. VERU-111, an Orally Available Tubulin Inhibitor, Suppresses Ovarian Tumor Growth and Metastasis. The Journal of Pharmacology and Experimental Therapeutics 2024:100006 View